Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

February 28, 2011

Study Completion Date

January 31, 2013

Conditions
Glioblastoma MultiformeGliosarcoma
Interventions
DRUG

Avastin

Avastin, by intravenous infusion, 10 mg/kg every 14 days

DRUG

Temozolomide

Oral temozolomide at 200 mg/m2 daily for 5 days

DRUG

Irinotecan

Irinotecan, by intravenous infusion, every other week (dose dependent upon if taking enzyme-inducing anti-epileptic drugs or if a blood test indicates the patient has the UGT 1A1 polymorphism)

Trial Locations (1)

27710

The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Katy Peters

OTHER